These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 34506040)

  • 1. The effect of oral bisphosphonate therapy on vertebral morphometry and fractures in patients with Duchenne muscular dystrophy and glucocorticoid-induced osteoporosis.
    Nasomyont N; Tian C; Hornung L; Khoury J; Hochwalt PM; Tilden JC; Wong BL; Rutter MM
    Muscle Nerve; 2021 Dec; 64(6):710-716. PubMed ID: 34506040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral bisphosphonate treatment in patients with Duchenne muscular dystrophy on long term glucocorticoid therapy.
    Tian C; Wong BL; Hornung L; Khoury JC; Rybalsky I; Shellenbarger KC; Rutter MM
    Neuromuscul Disord; 2020 Jul; 30(7):599-610. PubMed ID: 32680651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of teriparatide treatment for severe osteoporosis in patients with Duchenne muscular dystrophy.
    Nasomyont N; Keefe C; Tian C; Hornung L; Khoury J; Tilden JC; Hochwalt P; Jackson E; Rybalsky I; Wong BL; Rutter MM
    Osteoporos Int; 2020 Dec; 31(12):2449-2459. PubMed ID: 32676823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors associated with prevalent vertebral fractures in Duchenne muscular dystrophy.
    Phung K; McAdam L; Ma J; McMillan HJ; Jackowski S; Scharke M; Matzinger MA; Shenouda N; Koujok K; Jaremko JL; Smit K; Walker S; Hartigan C; Khan N; Konji VN; MacLeay L; Page M; Sykes E; Robinson ME; Alos N; Cummings EA; Ho J; Sbrocchi AM; Stein R; Saleh D; Craven BC; Dang UJ; Siminoski K; Rauch F; Ward LM
    Osteoporos Int; 2023 Jan; 34(1):147-160. PubMed ID: 36342539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of intravenous bisphosphonate therapy to treat vertebral fractures due to osteoporosis among boys with Duchenne muscular dystrophy.
    Sbrocchi AM; Rauch F; Jacob P; McCormick A; McMillan HJ; Matzinger MA; Ward LM
    Osteoporos Int; 2012 Nov; 23(11):2703-11. PubMed ID: 22297733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The time to and determinants of first fractures in boys with Duchenne muscular dystrophy.
    Ma J; McMillan HJ; Karagüzel G; Goodin C; Wasson J; Matzinger MA; DesClouds P; Cram D; Page M; Konji VN; Lentle B; Ward LM
    Osteoporos Int; 2017 Feb; 28(2):597-608. PubMed ID: 27774565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk Factors Associated with Incident Vertebral Fractures in Steroid-treated Males with Duchenne Muscular Dystrophy.
    Phung K; McAdam L; Ma J; McMillan HJ; Jackowski S; Scharke M; Matzinger MA; Shenouda N; Koujok K; Jaremko JL; Wilson N; Walker S; Hartigan C; Khan N; Page M; Robinson ME; Saleh DS; Smit K; Rauch F; Siminoski K; Ward LM
    J Clin Endocrinol Metab; 2024 Jan; 109(2):536-548. PubMed ID: 37610420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone health measures in glucocorticoid-treated ambulatory boys with Duchenne muscular dystrophy.
    Tian C; Wong BL; Hornung L; Khoury JC; Miller L; Bange J; Rybalsky I; Rutter MM
    Neuromuscul Disord; 2016 Nov; 26(11):760-767. PubMed ID: 27614576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Bisphosphonates on Osteoporosis Induced by Duchenne Muscular Dystrophy: A Prospective Study.
    Zheng WB; Dai Y; Hu J; Zhao DC; Wang O; Jiang Y; Xia WB; Xing XP; Li M
    Endocr Pract; 2020 Dec; 26(12):1477-1485. PubMed ID: 33471740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different bone health progression patterns and early-stage risk marker in glucocorticoid-treated ambulatory Duchenne muscular dystrophy.
    Zhou L; Zhou H; Xu H; Sun X; Chen X; Fan P; Cai X; Wang Q
    Osteoporos Int; 2024 Jun; 35(6):997-1005. PubMed ID: 38277031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reporting of paediatric osteoporotic vertebral fractures in Duchenne muscular dystrophy and potential impact on clinical management: the need for standardised and structured reporting.
    Martin H; Henderson A; Allen R; Childs AM; Dunne J; Horrocks I; Joseph S; Kraft JK; Ward K; Mushtaq T; Mason A; Kyriakou A; Wong SC
    Pediatr Radiol; 2024 Jan; 54(1):117-126. PubMed ID: 38072887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced bone mineral density in adolescents with Duchenne Muscular Dystrophy (DMD) and scoliosis.
    Tsaknakis K; Jäckle K; Lüders KA; Lorenz HM; Braunschweig L; Hell AK
    Osteoporos Int; 2022 Sep; 33(9):2011-2018. PubMed ID: 35583603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Skeletal findings in children recently initiating glucocorticoids for the treatment of nephrotic syndrome.
    Feber J; Gaboury I; Ni A; Alos N; Arora S; Bell L; Blydt-Hansen T; Clarson C; Filler G; Hay J; Hebert D; Lentle B; Matzinger M; Midgley J; Moher D; Pinsk M; Rauch F; Rodd C; Shenouda N; Siminoski K; Ward LM;
    Osteoporos Int; 2012 Feb; 23(2):751-60. PubMed ID: 21494860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advanced vertebral fracture among newly diagnosed children with acute lymphoblastic leukemia: results of the Canadian Steroid-Associated Osteoporosis in the Pediatric Population (STOPP) research program.
    Halton J; Gaboury I; Grant R; Alos N; Cummings EA; Matzinger M; Shenouda N; Lentle B; Abish S; Atkinson S; Cairney E; Dix D; Israels S; Stephure D; Wilson B; Hay J; Moher D; Rauch F; Siminoski K; Ward LM;
    J Bone Miner Res; 2009 Jul; 24(7):1326-34. PubMed ID: 19210218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vertebral Fractures in Duchenne Muscular Dystrophy Patients Managed With Deflazacort.
    Singh A; Schaeffer EK; Reilly CW
    J Pediatr Orthop; 2018 Jul; 38(6):320-324. PubMed ID: 27328118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone density and bone health alteration in boys with Duchenne Muscular Dystrophy: a prospective observational study.
    Suthar R; Reddy BVC; Malviya M; Sirari T; Attri SV; Patial A; Tageja M; Didwal G; Khandelwal NK; Saini AG; Saini L; Sahu JK; Dayal D; Sankhyan N
    J Pediatr Endocrinol Metab; 2021 May; 34(5):573-581. PubMed ID: 33838091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Denosumab for Glucocorticoid-Induced Osteoporosis in an Adolescent Patient with Duchenne Muscular Dystrophy: A Case Report.
    Kumaki D; Nakamura Y; Sakai N; Kosho T; Nakamura A; Hirabayashi S; Suzuki T; Kamimura M; Kato H
    JBJS Case Connect; 2018; 8(2):e22. PubMed ID: 29642113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of Neridronate in the Management of Bone Loss in Patients with Duchenne Muscular Dystrophy: Results from a Pilot Study.
    Moretti A; Liguori S; Paoletta M; Gimigliano F; Iolascon G
    Adv Ther; 2022 Jul; 39(7):3308-3315. PubMed ID: 35614293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient satisfaction and efficacy of switching from weekly bisphosphonates to monthly minodronate for treatment and prevention of glucocorticoid-induced osteoporosis in Japanese patients with systemic rheumatic diseases: a randomized, clinical trial.
    Tamechika SY; Sasaki K; Hayami Y; Ohmura SI; Maeda S; Iwagaitsu S; Naniwa T
    Arch Osteoporos; 2018 Jun; 13(1):67. PubMed ID: 29904824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fractures and Linear Growth in a Nationwide Cohort of Boys With Duchenne Muscular Dystrophy With and Without Glucocorticoid Treatment: Results From the UK NorthStar Database.
    Joseph S; Wang C; Bushby K; Guglieri M; Horrocks I; Straub V; Ahmed SF; Wong SC;
    JAMA Neurol; 2019 Jun; 76(6):701-709. PubMed ID: 30855644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.